JavaScript is unavailable or disabled; so you are probably going to miss out on a few things. Everything should still work, but with a little less pzazz!

The William Harvey Research Institute

Research menu


The William Harvey Research Institute (WHRI) at Queen Mary University of London (QMUL) conducts innovative, world-leading research in the fields of cardiovascular, endocrine and inflammation science. 

Founded in 1986 by the Nobel Laureate Sir John Vane, we have grown to become one of the largest multidisciplinary pharmacological institutes in Europe, with more than 400 staff and students from over 45 countries.

Our location within Barts and The London School of Medicine and Dentistry, and within QMUL provides a stimulating research environment, while close collaboration with Barts Health NHS Trust and healthcare partners across East London gives us a unique opportunity to translate and extend basic and clinical research into therapeutics that benefit the local community and beyond. 


    • In the 2014 Research Excellence Framework (REF) 90% of our research focused on therapeutic innovation in cardiovascular disease, inflammation and endocrinology, and was rated as world-leading or internationally excellent.
    • In Nature Journals our cardiovascular discoveries in hypertension, disorders of rhythm and coronary disease along with functional characterization have enabled new therapies and repurposing opportunities for unmet need. Using the translational platform of our successive NIHR Biomedical Research Centre (BRC) (£12m) we have created the £400M Barts Heart Centre where we developed and implemented NICE Guidance for hypertension (NICE 2011).
    • Our high-impact discoveries in inflammation on leucocyte migration, annexin, invention of new molecules targeting melanocortin are published in top journals and have been commercialised. Our MRC/NIHR funded stratified healthcare trials of biologic response in arthritis have generated worldwide pharma partnerships.
    • In endocrine research, our genomic discoveries in familial acromegaly have allowed us to stratify those who would benefit from early therapy avoiding shortened lives.
    • With an EU Cofund (€6M), an EU PhD scheme (€2.9M), BHF PhD and MRC MRes schemes we created the WHRI Translational Academy for Therapeutic Innovation to train future pharmacologists across the world. 

Learn more about our research areas 

Our research areas are aligned and integrated with the main themes pursued across Barts & The London School of Medicine and Dentistry. These include:

  • Genomics & Stratified Medicine
  • Experimental Medicine & Pharmacology
  • Translational Pharmacology & Therapeutic Innovation


Further information

Return to top